BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/6/2020 9:07:38 AM | Browse: 479 | Download: 824
Publication Name World Journal of Clinical Cases
Manuscript ID 59400
Country/Territory Japan
Received
2020-09-10 01:19
Peer-Review Started
2020-09-10 01:19
To Make the First Decision
Return for Revision
2020-09-23 05:23
Revised
2020-10-01 07:20
Second Decision
2020-10-19 06:43
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-10-20 02:58
Articles in Press
2020-10-20 02:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-11-02 16:35
Publish the Manuscript Online
2020-11-06 09:07
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Infectious Diseases
Manuscript Type Case Report
Article Title Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
Manuscript Source Unsolicited Manuscript
All Author List Masaki Okajima, Yoshinori Takahashi, Takaaki Kaji, Naohiko Ogawa and Hideyuki Mouri
ORCID
Author(s) ORCID Number
Masaki Okajima http://orcid.org/0000-0003-0184-3483
Yoshinori Takahashi http://orcid.org/0000-0001-8976-9614
Takaaki Kaji http://orcid.org/0000-0003-4932-0227
Naohiko Ogawa http://orcid.org/0000-0001-9495-7951
Hideyuki Mouri http://orcid.org/0000-0003-2478-0016
Funding Agency and Grant Number
Corresponding Author Masaki Okajima, MD, PhD, Assistant Professor, Intensive Care Unit, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa 920-8641, Ishikawa, Japan. mmokaji@gmail.com
Key Words COVID-19; Nafamostat; Hyperkalemia; Disseminated intravascular coagulation; Respiratory insufficiency; Case report
Core Tip The coronavirus disease 2019 (COVID-19) pandemic is a rapidly evolving situation. Nafamostat mesylate (NM) may prove to effective against COVID-19. However, our case series shows NM-induced hyperkalemia in 4 patients with COVID-19. Monitoring serum potassium levels after NM-initiation is imperative.
Publish Date 2020-11-06 09:07
Citation Okajima M, Takahashi Y, Kaji T, Ogawa N, Mouri H. Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports. World J Clin Cases 2020; 8(21): 5320-5325
URL https://www.wjgnet.com/2307-8960/full/v8/i21/5320.htm
DOI https://dx.doi.org/10.12998/wjcc.v8.i21.5320
Full Article (PDF) WJCC-8-5320.pdf
Full Article (Word) WJCC-8-5320.docx
CARE Checklist–2016 59400-CARE-Checklist–2016-revision.pdf
Manuscript File 59400_Auto_Edited.docx
Answering Reviewers 59400-Answering reviewers.pdf
Audio Core Tip 59400-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 59400-Conflict-of-interest statement.pdf
Copyright License Agreement 59400-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 59400-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate 59400-Language certificate.pdf
Peer-review Report 59400-Peer-review(s).pdf
Scientific Misconduct Check 59400-Scientific misconduct check.pdf
Scientific Editor Work List 59400-Scientific editor work list.pdf